Revvity, Inc. (RVTY) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Diagnostics & Research Branche. Der Hauptsitz des Unternehmens ist in Waltham, MA, United States. Der aktuelle CEO ist Prahlad R. Singh.
RVTY hat IPO-Datum 1965-07-06, 11,000 Vollzeitbeschäftigte, gelistet an der NYSE, eine Marktkapitalisierung von $10.45B.
Revvity, Inc. is a global provider of products, services, and solutions serving the diagnostics, life sciences, and applied services markets. Operating through two primary segments, Discovery & Analytical Solutions and Diagnostics, the company offers a comprehensive portfolio including analytical instruments, reagents, software, and imaging technologies for research and industrial applications across pharmaceuticals, environmental monitoring, food production, and chemical analysis. The Diagnostics segment specializes in instruments and assay platforms for genetic disorder detection, infectious disease testing, and genomic workflows, serving pharmaceutical companies, biotechnology firms, laboratories, academic institutions, and healthcare organizations worldwide. Founded in 1937 and headquartered in Waltham, Massachusetts, Revvity rebranded from PerkinElmer, Inc. in April 2023 to reflect its evolved market positioning and capabilities.
